BB Biotech AG/€BION
1D1W1MYTD1Y5YMAX
Capital at risk
About BB Biotech AG
BB Biotech AG is an investment company that focuses on investments in the biotechnology industry. The company is headquartered in Schaffhausen, Switzerland, and specializes in managing a portfolio primarily composed of companies involved in the development of innovative drugs and therapies. It seeks to capture growth opportunities in the biotech sector by investing in firms with cutting-edge scientific research and promising product pipelines. BB Biotech AG's investment strategy is informed by an in-depth analysis of market trends and scientific advancements, ensuring a dynamic and diversified portfolio. Its geographic footprint is primarily in Europe, with strategic investments in biotech firms globally.
- Ticker
- €BION
- Sector
- Finance
- Primary listing
- XGAT
- Employees
- 10
- Headquarters
- Küsnacht, Switzerland
BB Biotech AG Metrics
BasicAdvanced
€3B
2.14
€25.88
0.66
€2.46
4.44%
Price and volume
Market cap
€3B
Beta
0.66
52-week high
€60.90
52-week low
€37.70
Average daily volume
81K
Dividend rate
€2.46
Financial strength
Current ratio
583.969
Quick ratio
583.911
Dividend payout ratio (TTM)
9.20%
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
127.31%
Operating margin (TTM)
96.41%
Effective tax rate (TTM)
0.01%
Revenue per employee (TTM)
€112,003,930
Management effectiveness
Return on assets (TTM)
25.88%
Return on equity (TTM)
54.76%
Valuation
Price to earnings (TTM)
2.136
Price to revenue (TTM)
2.72
Price to book
0.93
Price to tangible book (TTM)
0.93
Price to free cash flow (TTM)
9.518
Free cash flow yield (TTM)
10.51%
Free cash flow per share (TTM)
5.81
Dividend yield (TTM)
4.44%
Forward dividend yield
4.44%
Growth
Revenue change (TTM)
-1,411.42%
Earnings per share change (TTM)
-405.52%
3-year revenue growth (CAGR)
3,595.30%
10-year revenue growth (CAGR)
23.30%
3-year earnings per share growth (CAGR)
144.24%
10-year earnings per share growth (CAGR)
1.00%
3-year dividend per share growth (CAGR)
-7.58%
10-year dividend per share growth (CAGR)
-2.51%
Bulls say / Bears say
BB Biotech’s Q2 2026 NAV returned 17.2% in CHF, outperforming the Nasdaq Biotechnology Index by 3.5 percentage points, while the company reported a CHF 451 million net profit versus a CHF 100 million loss a year earlier. (Financial Times)
Portfolio monetization remains a meaningful catalyst: three holdings were involved in announced M&A transactions during 2026, and eight portfolio companies were acquired over the preceding six quarters, supporting the value-realization case for BB Biotech’s active management. (Financial Times)
The portfolio was actively refreshed in Q2, with 12 new investments bringing total positions to 39; combined with the revised dividend policy targeting a 3–5% yield from fiscal 2026, this could improve both portfolio breadth and shareholder-return appeal. (Investegate)
The discount to NAV widened to 12.9% at June 30, 2026, even as the underlying NAV rose strongly, showing that portfolio gains may not translate into equivalent shareholder returns without a rerating. (Financial Times)
Reported earnings remain highly volatile because BB Biotech’s results largely reflect mark-to-market movements in its portfolio: Q1 2026 produced a CHF 21 million loss, while Q2 generated a CHF 451 million profit. (BB Biotech)
Despite the recent rebound, NAV performance over the five years to March 31, 2026 was still negative 10.4%, while reported portfolio volatility was 26.5%, highlighting substantial biotech-cycle and stock-selection risk. (BB Biotech)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.